Effects of rosuvastatin and ezetimibe on bone turnover markers in type 2 diabetes patients with hypercholesterolemia

Effects of rosuvastatin and ezetimibe on bone turnover markers in type 2 diabetes patients with hypercholesterolemia - Effects of rosuvastatin and ezetimibe on bone turnover markers

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001993

Enrollment

Registered

2009-05-21

Start date

2008-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypercholesterolemia with type 2 diabetes

Interventions

Rosuvastatin Ezetimibe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with newly diagnosed hypercholesterolemia, who visited our out clinic for education, evaluation, or treatment of type 2 diabetes, were enrolled if informed consent was obtained after a detailed explanation of the study purpose and methods.

Exclusion criteria

Exclusion criteria: Nobody had hepatic or renal dysfunction or nutritional derangements. All patients were free of drugs known to influence bone and calcium metabolism, such as vitamin D, bisphosphonate, or estrogen, up until the time of the study. Nobody had treatments with any cholesterol lowering agent.

Design outcomes

Primary

Measure	Time frame
Bone turnover markers	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026